> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Awards $16 Million in Rare Disease Treatment Grants
- URL: https://www.fdaweb.com/fda-awards-16-million-in-rare-disease-treatment-grants/
- Published: 2020-10-08T12:00:00.000Z
- Updated: 2026-09-14T16:31:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147834

FDA has awarded six new clinical trial research grants to principal investigators from academia and industry worth $16 million over the next four years. The grants, awarded through the Orphan Products Grants Program, enhance the development of medical products for patients with rare diseases, an agency [announcement](https://www.fda.gov/news-events/press-announcements/fda-awards-six-grants-fund-new-clinical-trials-advance-development-medical-products-treatment-rare?ref=fdaweb.com) says.

The agency says it received 47 applications that were reviewed and evaluated for scientific and technical merit by more than 90 rare disease and clinical trial experts. Grants went to: 

- Acuela, Inc., Seattle, WA, for a Phase 3 study of emixustat hydrochloride to treat Stargardt disease;
- Fred Hutchinson Cancer Research Center, Seattle, WA, for a Phase 2 study of ustekinumab for preventing graft versus host disease;
- Seattle Children’s Hospital, Seattle, WA, Phase 1b study of IV gallium nitrate for treating cystic fibrosis patients colonized with nontuberculosis mycobacterium;
- State University of New York Stony Brook, Stony Brook, NY, Phase 1 study of CD4 redirected chimeric antigen receptor T cell therapy for treating CD4 positive T cell neoplasms;
- University of Cincinnati, Cincinnati, OH, Phase 1/2 study of ABTLo812 (a small molecule with anti-cancer activity) for treating pancreatic cancer; and
- University of Virginia, Charlottesville, VA, Phase 2 study of oral azacytidine plus romidepsin for treating peripheral T cell lymphoma.